...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Pfizer seems like a good fit for a BP deal

I've been thinking about that for some time now narmac. If we are talking about both companies the the tax value is more like .60 to .70. RVX 330 million shares + ZEN 184 million shares into $300 million. That would be messy. Let hope it doesn't get to that.

tada 

Share
New Message
Please login to post a reply